Blood types, a critical factor in transfusion medicine, have study extensively since the early 20th century. The ABO blood group system, establish by Austrian immunologist Dr. Karl Landsteiner in 1901, introduce the understanding of four main blood types, A, B, AB, and O.
These discoveries, which earn Landsteiner the 1930 Nobel Prize in Physiology or Medicine, revolutionised the practice of blood transfusions.
But, according to recent findings and expert input, it has reveal that the complexity of blood types extends far beyond the ABO system and Rh factor classification.
As per studies, blood types are define by antigens, proteins and sugars present on the surface of red blood cells.
Dr. Emily Coberly, Divisional Chief Medical Officer at the American Red Cross, said that the ABO system is pivotal in transfusion compatibility.
Individuals produce antibodies against antigens not present in their own blood type, leading to immune reactions if mismatch blood is transfuse.
The Rh factor, another major antigen, determines whether blood is classified as positive or negative.
These components combine to create the eight primary blood groups.
After the ABO and Rh classifications, more than 350 other antigens have identified on red blood cells.
The International Society of Blood Transfusion currently recognises 47 blood group systems, with additional discoveries continually expanding this number.
Rare blood types, such as the McLeod phenotype and Bombay phenotype, arise from unique antigen combinations.
These rare types can complicate transfusions for individuals with specific conditions like sickle cell disease, which predominantly affects African and Hispanic populations.
According to reports, maintaining a diverse blood donor base is essential.
Dr. Emily Coberly, in a statement, has stress the importance of matching blood more closely for patients with rare blood types, ensuring safe and effective treatments.
According to reports, researchers are also exploring innovations to create universal donor blood by modifying red blood cells or engineering them from scratch, aiming to overcome compatibility challenges.
